Europe Peptide Therapeutics Market

Europe Peptide Therapeutics Market Size (2024 to 2029)

The size of the European peptide therapeutics market is expected to project a promising CAGR of 9.5% during the forecast period.

The growing prevalence of chronic and metabolic disorders across Europe primarily drives the growth of the European peptide therapeutics market.

Peptide-based therapies are derived from naturally occurring peptides in the human body that offer the potential for hormone growth, neurotransmission and anti-infective treatments. With approximately 7,000 naturally occurring peptides identified, peptide therapeutics help maintain balanced peptide levels. The rising number of cancer cases in Europe, reported at around 1.4 million in males and 1.2 million in females, has led to increased demand for peptide therapeutics in cancer treatment. Researchers are focused on diagnosing and treating cancer early to improve patient outcomes, and peptide-based therapies have shown promise in this area. Recombinant peptides and laboratory-developed peptides are utilized in the treatment of cancer, contributing to the advancement of anticancer therapies.

An increasing number of advancements in the development of new therapies and treatments further boost the growth rate of the European peptide therapeutics market. Researchers are focusing on peptide-based therapies for various diseases, including oral peptide drug nanoparticles for managing glucose levels in diabetic patients. The growing support from healthcare organizations, investments from public and private organizations, and the approval of therapies and drugs contribute to market growth in the European region.

The growing demand for peptide therapeutics in the treatment of various diseases, rapid adoption of peptide-based therapies for cancer treatment, advancements in the development of new therapies and drugs based on peptides and growing focus on the development of oral peptide drug nanoparticles for diabetes management boost the growth rate of the European peptide therapeutics market.

Support from healthcare organizations for peptide therapeutics research and development, increased investment from public and private organizations in peptide therapy development, growing number of therapy and drug approvals for peptide-based treatments, rising awareness among healthcare professionals about the benefits of peptide therapeutics and favorable government regulations and policies supporting the use of peptide therapeutics in healthcare boost the growth rate of the European market.The high cost of novel peptide drug development is one of the key factors hampering the growth of the European peptide therapeutics market. Lack of awareness, shortage of skilled professionals, stringent regulations, and inadequate reimbursement policies impede market growth in Europe. The side effects associated with peptide therapeutics such as numbness of hands and feet and fatigue hinders the market's growth rate in the European region.

Impact Of Covid-19 On The European Peptide Therapeutics Market

New peptides are being developed and reused as therapeutics for the treatment of COVID-19. Many researchers worldwide continue to search for products that will block important mechanisms of SARS-CoV-2 infection and help replication or treat conditions caused by the infection. In 2020, the FDA updated its biological definition to include chemically synthesized polypeptides of more than 40 amino acids but less than 100 amino acids (synthetic proteins) and synthetic peptides of 40 amino acids or less. As of May 2020, 22 peptide drugs were in the development stage for the treatment of Covid-19 infection, which includes 15 synthetic peptides for the treatment of acute respiratory distress syndrome (ARDS) and other respiratory diseases caused by SARS-COV infection; hence the European peptide therapeutics market is expected to have a positive impact.

This research report on the European peptide therapeutics market has been segmented and sub-segmented into the following categories

Europe Peptide Therapeutics Market - By Type

• Generic
• Innovative

Europe Peptide Therapeutics Market- By Application

• Metabolic
• Cardiovascular Disorder
• Respiratory
• GIT
• Anti-infection
• Pain
• Dermatology
• CNS
• Renal
• Others

Europe Peptide Therapeutics Market - By Type of Manufacturers

• In-house
• Outsourced

Europe Peptide Therapeutics Market -By Route of Administration

• Parenteral Route
• Oral Route
• Pulmonary
• Mucosal
• Others

Europe Peptide Therapeutics Market - By Synthesis Technology

• Solid Phase Peptide Synthesis (SPPS)
• Liquid Phase Peptide Synthesis (LPPS)
• Hybrid Technology

Europe Peptide Therapeutics Market - By Country

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Europe had a substantial share of the global market in 2023 and is expected to grow at a healthy CAGR during the forecast period owing to the widespread adoption of peptide therapeutics, increased healthcare spending, initiatives from the governments of European countries to facilitate the introduction of novel drugs and therapies and awareness campaigns promoting the benefits of peptide therapies.

Germany led the peptide therapeutics market in Europe in 2023 and is expected to continue to lead the regional market throughout the forecast period. The availability of a robust pharmaceutical industry, increasing manufacturing activities of peptide drugs and advanced laboratory facilities in Germany drive the German market growth. The availability of peptide drugs in medical stores and pharmacies further fuels the growth rate of the German market.

The UK peptide therapeutics market is anticipated to grow at a prominent CAGR during the forecast period owing to the presence of clinical trial centers and hospitals adopting peptide therapies, manufacturing capabilities that ensure the production of high-quality peptides.

KEY MARKET PLAYERS

Companies playing a significant role in the European peptide therapeutics market profiled in this report are Eli Lilly and Company, Amgen, Inc., Pfizer, Inc., Bristol-Myers Squibb Company, Ever Neuro Pharma GmbH, Takeda Pharmaceutical Company Limited, AstraZeneca PLC, GlaxoSmithKline plc, Novo Nordisk A/S., Novartis AG, Zealand Pharma AG, AmbioPharm Inc., Bachem Holding AG, PolyPeptide Group, Sanofi SA, Amylin Pharmaceuticals, CirclePharma, Inc., PeptiDream Inc., Apitope Technology, Arch NioPartners, and Galena Biopharmaceuticals.